section name header

Pronunciation

ZOE-pi-clone

Classifications

Therapeutic Classification: sedative/hypnotics

Pharmacologic Classification: cyclopyrrolones

Indications

REMS


Action

  • Interacts with GABA-receptor complexes; not a benzodiazepine.
Therapeutic effects:
  • Improved sleep with decreased latency and increased maintenance of sleep.

Pharmacokinetics

Absorption: Rapidly absorbed (75%) following oral administration.

Distribution: Rapidly distributed from extravascular compartment. Enters breast milk in concentrations that are 50% of plasma levels.

Metabolism/Excretion: Extensively metabolized (mostly by the CYP3A4 enzyme system), metabolites have minimal sedative/hypnotic activity; 4–5% excreted unchanged in urine.

Half-Life: 5 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
POrapid2 hr6 hr



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: abnormal thinking, behavioral changes, sleep-driving

GI: bitter taste, anorexia, constipation, dry mouth, dyspepsia

Misc: allergic reactions including anaphylaxis, anaphylactoid reactions, and angioedema

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

Canadian Brand Names

Imovane